News ArticleShriram Finance Schedules Group Meeting with Select Investors at JM Financial India Xchange 2026 on November 16, 2026
Senior management to engage with investors in Mumbai, focusing on investor presentation and public disclosures
Shriram Finance Limited announces a group meeting with select investors scheduled for November 16, 2026, in Mumbai during the JM Financial India Xchange 2026. The senior management will present and discuss investor presentations and public disclosures, providing engagement opportunities for institutional investors and analysts.
Shriram Finance Limited
Investor Presentation
Shriram Finance Limited has announced a group meeting with select investors to be held on November 16, 2026, in Mumbai at the JM Financial India Xchange 2026 event. The company's senior management will participate to discuss investor presentations and public disclosures.
The group meeting is scheduled in Mumbai and will include participation from the Senior Management and Management Personnel of Shriram Finance Limited.
Details of the meeting have been shared in compliance with Regulation 30 of SEBI's Listing Obligations and Disclosure Requirements Regulations, 2015.
The discussion during the meeting will centre on the investor presentation and information already available in the public domain.
This interaction is part of Shriram Finance’s ongoing engagement with institutional investors, analysts, brokers, and other market participants to enhance transparency and communication.
Highlights
- Group meeting scheduled on November 16, 2026, in Mumbai.
- Meeting part of JM Financial India Xchange 2026 event.
- Senior management to attend and present investor information.
- Discussion based on investor presentation and public disclosures.
- Complies with SEBI’s Listing Regulations, Regulation 30.
Key Data Snapshot
What happened
- Shriram Finance announced a group meeting with select investors at JM Financial India Xchange 2026.
- The meeting is scheduled for November 16, 2026, in Mumbai and will include senior management participation.
- The purpose is to discuss the investor presentation and information available to the public.
Key details
- Meeting scheduled pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- Participation includes institutional investors, analysts, brokers, and management personnel.
- The company has disclosed these details on its website as well.
Highlights
- Group meeting scheduled on November 16, 2026, in Mumbai.
- Meeting part of JM Financial India Xchange 2026 event.
- Senior management to attend and present investor information.
- Discussion based on investor presentation and public disclosures.
- Complies with SEBI’s Listing Regulations, Regulation 30.
Disclosures
- Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015
More News on Investor Presentation
View allLatest corporate announcements and market updates in Investor Presentation.
Rubicon Research Limited Reports Nearly 40% Revenue Growth and 68% Profit Increase in Q2 FY26-27
Rubicon Research Limited posted significant financial growth for the quarter ended September 30, 2026, with revenue increasing by 39.9% year-on-year to ₹5,764 million and profit after tax rising 67.9% to ₹904 million. This performance includes the consolidation impact of its recent Arinna acquisition and reflects strong operational cash flows and product approvals.
Read Full Story
Inventurus Knowledge Solutions Reports Q2 FY27 Investor Presentation Highlighting AI-Driven Growth and Platform Innovation
Inventurus Knowledge Solutions Limited disclosed its investor presentation for the quarter and half-year ended September 30, 2026, emphasizing advancements in its AI-powered healthcare enablement platform, strategic execution plans, and ongoing partnerships to drive growth and optimize margins.
Read Full Story
Sai Life Sciences Reports 23% Revenue Growth in Q2 FY27 with ₹659 Crore Revenue Amid Strategic Expansion
Sai Life Sciences Limited announced a 23% year-over-year revenue growth to ₹659 crore for the second quarter of fiscal year 2027, supported by healthy performance in both its Contract Research (CRO) and Contract Development and Manufacturing Organization (CDMO) segments. The company reported an EBITDA margin of 28% and continued its capital expenditure with ₹621 crore invested in the first half of FY27 to expand capacity and capabilities.
Read Full Story
